Frankfurt
01.07.26 | 20:09
0,642 Euro
+105,77 % +0,330
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Mi | QuantumCell commits $2.2bn on AlzeCure's Alzheimer's platform | 2 | Pharmaceutical Technology | ||
| Mi | Backed by top-tier VCs, stealthy biotech bags AlzeCure Alzheimer's asset in $2.2B deal | 4 | FierceBiotech | ||
| Mi | AlzeCure Pharma Aktie schießt nach milliardenschwerem Lizenzdeal in die Höhe | 5 | Investing.com Deutsch | ||
| Mi | AlzeCure-Aktie: Milliarden-Deal treibt Kurs auf Hoch seit 2022 | 1 | Investing.com Deutsch | ||
| Mi | AlzeCure Pharma Enters an Out-Licensing and Collaboration Agreement with QuantumCell ApS for the NeuroRestore ACD856 Project | 251 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / July 1, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| Mo | Communique from the Annual General Meeting of AlzeCure Pharma on 29 June 2026 | 477 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 29, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - Today, 29 June 2026, the annual general meeting was held in AlzeCure Pharma AB (publ) (the "Company"). Below... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: Positive results from the Phase Ib clinical study of NeuroRestore ACD856, under development for Alzheimer's | 409 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's disease and pain, today announced that... ► Artikel lesen | |
| 16.06. | AlzeCure Pharma AB: The subscription period in AlzeCure Pharma's Rights Issue begins today | 245 | GlobeNewswire (Europe) | THIS PRESS RELEASE MAY NOT BE PUBLISHED, RELEASED OR DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO RUSSIA, BELARUS, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH... ► Artikel lesen | |
| ALZECURE PHARMA Aktie jetzt für 0€ handeln | |||||
| 15.06. | Listing of subscription rights and paid subscription shares of AlzeCure Pharma AB | 167 | GlobeNewswire | With effect from June 16, 2026, the subscription rights in AlzeCure Pharma AB will be traded on First North Growth Market. Trading will continue up until and including June 25, 2026.
... ► Artikel lesen | |
| 10.06. | Eli Lilly continues dealmaking roll with $1bn AlzeCure agreement | 6 | Pharmaceutical Technology | ||
| 10.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 10.06.2026 | 227 | Xetra Newsboard | Das Instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 10.06.2026 und ex Kapitalmassnahme am 11.06.2026 The instrument AC6 SE0010133785 ALZECURE PHARMA AB EQUITY... ► Artikel lesen | |
| 09.06. | Lilly moves deeper into Alzheimer's research with AlzeCure licensing deal | 8 | FierceBiotech | ||
| 09.06. | Lilly, AlzeCure ink Alzheimer's drug deal worth more than $1B | 11 | Seeking Alpha | ||
| 09.06. | 1-Milliarde-Deal: Alzheimer-Hammer: Lilly schickt Mini-Biotech um 553 % nach oben | 778 | wallstreetONLINE | © Foto: OpenAIEli Lilly setzt mit AlzeCure auf eine Alzheimer-Tablette - und lässt die Aktie des kleinen Biotechs um mehr als 550 Prozent explodieren.Eli Lilly hat mit AlzeCure Pharma einen Kooperations-... ► Artikel lesen | |
| 09.06. | AlzeCure-Aktie explodiert um 301 % nach Alzheimer-Deal mit Eli Lilly | 19 | Investing.com Deutsch | ||
| 09.06. | AlzeCure Pharma Enters Into A Collaboration And Out-Licensing Agreement With Lilly For Alzheimer's Project | 1.286 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / June 9, 2026 / AlzeCure Pharma AB (publ) ("AlzeCure")(STO:ALZCUR)(FRA:AC6), which develops small-molecule drug candidates for CNS diseases with a focus on Alzheimer's... ► Artikel lesen | |
| 05.06. | AlzeCure Pharma AB: AlzeCure Pharma carries out previously announced rights issue of approximately SEK 30.1 million and publishes information document | 319 | GlobeNewswire (Europe) | AlzeCure Pharma AB (publ) (FN STO: ALZCUR), which develops small molecule drug candidates for CNS disorders, with a focus on Alzheimer's disease and pain, has today resolved to proceed with the rights... ► Artikel lesen | |
| 26.05. | Notice To Annual General Meeting in AlzeCure Pharma AB | 484 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 26, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6) - The shareholders of AlzeCure Pharma AB, reg. no. 559094-8302 (the "Company") are hereby invited to attend the... ► Artikel lesen | |
| 19.05. | AlzeCure Pharma to Host Live Seminar on The Pain Project TrkA-NAM ACD137 with a Focus on Osteoarthritis and Neuropathic Pain | 393 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 19, 2026 / AlzeCure Pharma AB (publ) (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing... ► Artikel lesen | |
| 13.05. | AlzeCure Pharma to Present at Redeye Investor Forum Online on May 21 | 279 | ACCESS Newswire | STOCKHOLM, SE / ACCESS Newswire / May 13, 2026 / AlzeCure Pharma (STO:ALZCUR)(FRA:AC6), a biotech company that develops candidate drugs for diseases affecting the nervous system, focusing on Alzheimer's... ► Artikel lesen |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| VERTEX PHARMACEUTICALS | 438,00 | +0,77 % | Innovation in der Forschung: Chancen bei Vertex Pharmaceuticals, BioNxt Solutions und BioNTech! | In Sozialen Medien findet man allerlei negative Kommentare und Memes zum Pfizer Konzern. Eine sehr populäre Behauptung lautet, dass der von deutschen Einwanderern in New York gegründete Konzern (Karl... ► Artikel lesen | |
| VIATRIS | 14,176 | +1,97 % | Viatris Reports Positive Results From Phase 3 IgAN Trial In Japan | WASHINGTON (dpa-AFX) - Viatris Inc. (VTRS), a healthcare company, on Monday reported positive top-line results from a Phase 3 study evaluating VR-205 in Japanese adults with primary immunoglobulin... ► Artikel lesen | |
| ALTIMMUNE | 2,815 | +6,03 % | Altimmune, Inc: Altimmune Announces First Quarter 2026 Financial Results and Business Update | Initiation of PERFORMA Phase 3 MASH trial planned for second half 2026 $535 million in cash, cash equivalents and short-term investments as of April 30, 2026 Webcast to be held today at 8:30 a.m.... ► Artikel lesen | |
| SELLAS LIFE SCIENCES | 11,850 | -8,49 % | Sellas Life Sciences: Optionshandel steigt auf 66.504 Kontrakte | ||
| OPKO HEALTH | 1,310 | -0,76 % | OPKO Health, Inc.: OPKO Health Reports First Quarter 2026 Business Highlights and Financial Results | MIAMI, April 28, 2026 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) (OPKO) reports business highlights and financial results for the three months ended March 31, 2026. Highlights from the first... ► Artikel lesen | |
| JAGUAR HEALTH | 2,975 | -0,83 % | Jaguar Health, Inc.: Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure | Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseasesNear-term milestones for IF program buttressed by continuing groundbreaking results of study... ► Artikel lesen | |
| AURINIA PHARMACEUTICALS | 15,060 | +1,38 % | Alliance Advisors LLC: Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences | Little Falls, New Jersey--(Newsfile Corp. - May 19, 2026) - Alliance Advisors is pleased to congratulate Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) on the successful completion of its tender offer... ► Artikel lesen | |
| KIORA PHARMACEUTICALS | 2,660 | +1,14 % | Kiora Pharmaceuticals, Inc.: Kiora Pharmaceuticals Reports its Ion Channel Modulator, KIO-300, Suppressed Seizure Activity in Preclinical Epilepsy Model | Encinitas, California--(Newsfile Corp. - June 18, 2026) - Kiora Pharmaceuticals (NASDAQ: KPRX) today announced preclinical data showing that KIO-300, part of the company's novel ion channel modulator... ► Artikel lesen | |
| LIPOCINE | 2,480 | -3,12 % | Lipocine Inc.: Lipocine Announces Financial Results for the First Quarter Ended March 31, 2026 | SALT LAKE CITY, May 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a biopharmaceutical company leveraging its proprietary technology platform to augment... ► Artikel lesen | |
| ACLARIS THERAPEUTICS | 4,766 | +2,85 % | Strength Seen in Aclaris (ACRS): Can Its 5.4% Jump Turn into More Strength? | ||
| PHOTOCURE | 5,160 | -0,96 % | Photocure ASA - CFO transition | ||
| EUROBIO SCIENTIFIC | 21,400 | 0,00 % | Eurobio Scientific finalizes the acquisition of CareDX's transplant Lab Product division | EUROBIO SCIENTIFIC FINALIZES THE ACQUISITION OF CAREDX's TRANSPLANT LAB PRODUCT DIVISION Acceleration of Eurobio's strategic plan to become an in-vitro molecular diagnostics ("IVD") leaderCreation... ► Artikel lesen | |
| MEDICURE | 0,780 | +1,30 % | Medicure, Inc.: Medicure Announces AGM Results and Appointment of New Director | WINNIPEG, MB / ACCESS Newswire / May 21, 2026 / Medicure Inc. ("Medicure" or the "Company") (TSXV:MPH)(OTC:MCUJF), a company focused on the development and commercialization of pharmaceuticals and healthcare... ► Artikel lesen | |
| BAYER | 49,000 | +1,22 % | Krebs bleibt die heißeste Wette im Pharmamarkt: Bayer, Vidac Pharma und Pfizer kämpfen um die nächste Therapiegeneration | Der Onkologie-Markt ist der heißeste Bereich der Pharmaindustrie. Während globale Schwergewichte ihre milliardenschweren Pipelines in Stellung bringen, setzt ein kleines Biotech auf einen wissenschaftlichen... ► Artikel lesen | |
| MERCK KGAA | 144,50 | -1,60 % | EQS-PVR: Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Merck KGaA
Merck KGaA: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
24.06.2026 / 09:18 CET/CEST
Veröffentlichung... ► Artikel lesen |
ALZECURE PHARMA AB gehört der Branche Pharma an. Mit einer aktuellen Kursveränderung von +0,330 (+105,77 %) liegt der Kurs bei 0,642 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALZECURE PHARMA AB finden Sie auf Wallstreet Online.